Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study
Abstract Aims The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real‐world cohort of patients with heart failure with reduced ejection fraction (HFrEF). Methods This study is a prospective and observational cohort study of patients with HFrE...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.15032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850105821384409088 |
|---|---|
| author | Mario Galván Ruiz Miguel Fernández de Sanmamed Girón María delVal Groba Marco Lorena Rojo Jorge Claudia Peña Saavedra Elvira Martín Bou Rubén Andrade Guerra Eduardo Caballero Dorta Antonio García Quintana |
| author_facet | Mario Galván Ruiz Miguel Fernández de Sanmamed Girón María delVal Groba Marco Lorena Rojo Jorge Claudia Peña Saavedra Elvira Martín Bou Rubén Andrade Guerra Eduardo Caballero Dorta Antonio García Quintana |
| author_sort | Mario Galván Ruiz |
| collection | DOAJ |
| description | Abstract Aims The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real‐world cohort of patients with heart failure with reduced ejection fraction (HFrEF). Methods This study is a prospective and observational cohort study of patients with HFrEF and recent HF worsening episodes requiring intravenous therapy who initiated vericiguat in an HF outpatient clinic. A subanalysis of patients with ≥6 months' follow‐up was performed separately. Results Out of 103 patients initially included, 52 had a follow‐up of at least 6 months (median follow‐up of 303 days). At baseline, the mean age was 71.3 ± 9.4 years, 27.2% were women, the median left ventricular ejection fraction was 34% (28%–39%) and 99% were taking beta‐blockers, 96.1% sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, 95.1% sacubitril–valsartan, 90.3% aldosterone antagonists and 93.2% loop diuretics. During follow‐up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P < 0.001), as did the EuroQol‐5D (EQ‐5D) and visual analogue scale (VAS) scores (from 0.83 ± 0.13 to 0.87 ± 0.12, P = 0.032, and from 60 to 79, P = 0.005, respectively). Vericiguat was well tolerated (13.5% had symptomatic hypotension, and 11.5% had discontinued treatment), and 78.8% of patients achieved the target dose of 10 mg. The number of HF‐related hospitalizations/decompensations within the previous 12 months was 2.3 ± 1.4 and decreased with vericiguat to 0.79 ± 1.14 (P < 0.001). At study end, 7.7% died (50% for HF). Conclusions In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects. |
| format | Article |
| id | doaj-art-57bd1f0cb5a749da91125b1ae9c8ebc0 |
| institution | OA Journals |
| issn | 2055-5822 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-57bd1f0cb5a749da91125b1ae9c8ebc02025-08-20T02:38:58ZengWileyESC Heart Failure2055-58222024-12-011164222423010.1002/ehf2.15032Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA studyMario Galván Ruiz0Miguel Fernández de Sanmamed Girón1María delVal Groba Marco2Lorena Rojo Jorge3Claudia Peña Saavedra4Elvira Martín Bou5Rubén Andrade Guerra6Eduardo Caballero Dorta7Antonio García Quintana8Department of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainHospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainDepartment of Cardiology Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria SpainAbstract Aims The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real‐world cohort of patients with heart failure with reduced ejection fraction (HFrEF). Methods This study is a prospective and observational cohort study of patients with HFrEF and recent HF worsening episodes requiring intravenous therapy who initiated vericiguat in an HF outpatient clinic. A subanalysis of patients with ≥6 months' follow‐up was performed separately. Results Out of 103 patients initially included, 52 had a follow‐up of at least 6 months (median follow‐up of 303 days). At baseline, the mean age was 71.3 ± 9.4 years, 27.2% were women, the median left ventricular ejection fraction was 34% (28%–39%) and 99% were taking beta‐blockers, 96.1% sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, 95.1% sacubitril–valsartan, 90.3% aldosterone antagonists and 93.2% loop diuretics. During follow‐up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P < 0.001), as did the EuroQol‐5D (EQ‐5D) and visual analogue scale (VAS) scores (from 0.83 ± 0.13 to 0.87 ± 0.12, P = 0.032, and from 60 to 79, P = 0.005, respectively). Vericiguat was well tolerated (13.5% had symptomatic hypotension, and 11.5% had discontinued treatment), and 78.8% of patients achieved the target dose of 10 mg. The number of HF‐related hospitalizations/decompensations within the previous 12 months was 2.3 ± 1.4 and decreased with vericiguat to 0.79 ± 1.14 (P < 0.001). At study end, 7.7% died (50% for HF). Conclusions In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.https://doi.org/10.1002/ehf2.15032heart failurehospitalizationvericiguat |
| spellingShingle | Mario Galván Ruiz Miguel Fernández de Sanmamed Girón María delVal Groba Marco Lorena Rojo Jorge Claudia Peña Saavedra Elvira Martín Bou Rubén Andrade Guerra Eduardo Caballero Dorta Antonio García Quintana Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study ESC Heart Failure heart failure hospitalization vericiguat |
| title | Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study |
| title_full | Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study |
| title_fullStr | Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study |
| title_full_unstemmed | Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study |
| title_short | Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study |
| title_sort | clinical profile associated events and safety of vericiguat in a real world cohort the verita study |
| topic | heart failure hospitalization vericiguat |
| url | https://doi.org/10.1002/ehf2.15032 |
| work_keys_str_mv | AT mariogalvanruiz clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT miguelfernandezdesanmamedgiron clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT mariadelvalgrobamarco clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT lorenarojojorge clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT claudiapenasaavedra clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT elviramartinbou clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT rubenandradeguerra clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT eduardocaballerodorta clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy AT antoniogarciaquintana clinicalprofileassociatedeventsandsafetyofvericiguatinarealworldcohorttheveritastudy |